These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 27487127)
21. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27 Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665 [TBL] [Abstract][Full Text] [Related]
22. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Hu Y; Xu K; Yagüe E Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794 [TBL] [Abstract][Full Text] [Related]
23. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells. Hu D; Li M; Su J; Miao K; Qiu X Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260 [TBL] [Abstract][Full Text] [Related]
24. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts. Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714 [TBL] [Abstract][Full Text] [Related]
25. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Li XJ; Ji MH; Zhong SL; Zha QB; Xu JJ; Zhao JH; Tang JH Arch Med Res; 2012 Oct; 43(7):514-21. PubMed ID: 23085450 [TBL] [Abstract][Full Text] [Related]
26. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells. Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637 [TBL] [Abstract][Full Text] [Related]
27. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells. Sun FD; Wang PC; Luan RL; Zou SH; Du X Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492 [TBL] [Abstract][Full Text] [Related]
28. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway. Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606 [TBL] [Abstract][Full Text] [Related]
30. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer. Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756 [TBL] [Abstract][Full Text] [Related]
31. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. Kim B; Stephen SL; Hanby AM; Horgan K; Perry SL; Richardson J; Roundhill EA; Valleley EM; Verghese ET; Williams BJ; Thorne JL; Hughes TA BMC Cancer; 2015 Sep; 15():634. PubMed ID: 26362310 [TBL] [Abstract][Full Text] [Related]
32. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. Ding J; Zhao Z; Song J; Luo B; Huang L Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752 [TBL] [Abstract][Full Text] [Related]
33. MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Lu L; Ju F; Zhao H; Ma X Biotechnol Lett; 2015 Dec; 37(12):2387-94. PubMed ID: 26318721 [TBL] [Abstract][Full Text] [Related]
34. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498 [TBL] [Abstract][Full Text] [Related]
35. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778 [TBL] [Abstract][Full Text] [Related]
36. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Dönmez Y; Gündüz U Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614 [TBL] [Abstract][Full Text] [Related]
37. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Louisa M; Soediro TM; Suyatna FD Asian Pac J Cancer Prev; 2014; 15(4):1639-42. PubMed ID: 24641381 [TBL] [Abstract][Full Text] [Related]
38. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856 [TBL] [Abstract][Full Text] [Related]
39. Regulation of Mucin 1 and multidrug resistance protein 1 by honokiol enhances the efficacy of doxorubicin-mediated growth suppression in mammary carcinoma cells. Thulasiraman P; Johnson AB Int J Oncol; 2016 Aug; 49(2):479-86. PubMed ID: 27221150 [TBL] [Abstract][Full Text] [Related]
40. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]